Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Cuzick

Showing results (131-140 of 229) with videos related to

Pageof 23
Sort By:
British Journal of Haematology|August 1, 1990
Long-term prognostic value of serum beta 2 microglobulin in myelomatosisJ Cuzick, B L De Stavola, E H Cooper, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|October 1, 1987
A trial of human alpha interferon as an adjuvant agent in breast cancer after loco-regional recurrenceI S Fentiman, F R Balkwill, J Cuzick, et al.
Cancer|October 30, 2003
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analysesM Baum, A Buzdar, J Cuzick, et al.
British Journal of Cancer|November 13, 2008
Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancerB Sherrill, M Amonkar, Y Wu, et al.
Lancet (London, England)|May 22, 2007
Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials, J Cuzick, L Ambroisine, et al.
International Journal of Colorectal Disease|February 1, 1987
Value of flow cytometric determination of ploidy as a guide to prognosis in operable rectal cancer: a multivariate analysisH S Goh, J R Jass, W S Atkin, et al.
Lancet (London, England)|February 1, 2003
Overview of the main outcomes in breast-cancer prevention trialsJ Cuzick, T Powles, U Veronesi, et al.
International Journal of Cancer|March 3, 1995
Risk of ocular melanoma in relation to cutaneous and iris naeviV Bataille, P Sasieni, J Cuzick, et al.
Archives of Dermatology|February 1, 1993
Five cases of coexistent primary ocular and cutaneous melanomaV Bataille, E Pinney, J L Hungerford, et al.
Hematological Oncology|April 1, 1988
Results of the MRC myelomatosis trials for patients entered since 1980I C MacLennan, K Kelly, R A Crockson, et al.
Pageof 23

Showing results (131-140 of 229) with videos related to

Sort By:
Pageof 23
British Journal of Haematology|August 1, 1990
Long-term prognostic value of serum beta 2 microglobulin in myelomatosisJ Cuzick, B L De Stavola, E H Cooper, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|October 1, 1987
A trial of human alpha interferon as an adjuvant agent in breast cancer after loco-regional recurrenceI S Fentiman, F R Balkwill, J Cuzick, et al.
Cancer|October 30, 2003
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analysesM Baum, A Buzdar, J Cuzick, et al.
British Journal of Cancer|November 13, 2008
Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancerB Sherrill, M Amonkar, Y Wu, et al.
Lancet (London, England)|May 22, 2007
Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials, J Cuzick, L Ambroisine, et al.
International Journal of Colorectal Disease|February 1, 1987
Value of flow cytometric determination of ploidy as a guide to prognosis in operable rectal cancer: a multivariate analysisH S Goh, J R Jass, W S Atkin, et al.
Lancet (London, England)|February 1, 2003
Overview of the main outcomes in breast-cancer prevention trialsJ Cuzick, T Powles, U Veronesi, et al.
International Journal of Cancer|March 3, 1995
Risk of ocular melanoma in relation to cutaneous and iris naeviV Bataille, P Sasieni, J Cuzick, et al.
Archives of Dermatology|February 1, 1993
Five cases of coexistent primary ocular and cutaneous melanomaV Bataille, E Pinney, J L Hungerford, et al.
Hematological Oncology|April 1, 1988
Results of the MRC myelomatosis trials for patients entered since 1980I C MacLennan, K Kelly, R A Crockson, et al.
Pageof 23